Welcome to our dedicated page for MAIA Biotechnology SEC filings (Ticker: MAIA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MAIA Biotechnology, Inc. filings document the regulatory record for a clinical-stage oncology company developing ateganosine for non-small cell lung cancer. Form 8-K reports cover THIO-101 clinical updates, oncology conference materials, shareholder communications on the development pipeline, FDA Fast Track disclosure, and forward-looking risk language tied to investigational drug development.
The company’s filings also document capital structure and governance matters, including an underwritten common stock offering conducted under an effective Form S-3 shelf registration, the related underwriting agreement and use-of-proceeds disclosure, executive compensation actions, and annual meeting proxy matters such as director elections and auditor ratification.
MAIA Biotechnology, Inc. Chief Executive Officer and director Vitoc Vlad reported an open-market purchase of 72,700 shares of common stock. The shares were bought at a weighted average price of $1.3877 per share, across multiple trades priced between $1.3634 and $1.4150.
Following this purchase, Vlad directly holds 976,121 shares of MAIA common stock. The filing also notes an additional 210,100 shares of common stock beneficially owned by his spouse, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.
MAIA Biotechnology director Stan Smith, through an indirect trust ownership, reported an open-market purchase of 75,000 shares of Common Stock of MAIA Biotechnology at a weighted average price of $1.336 per share. The filing states the shares were bought in multiple trades between $1.32 and $1.40.
After this transaction, an entity associated with Smith held 1,519,178 shares indirectly. Additional indirect holdings of 4,580 shares are shown in separate trust accounts for family members, where Smith disclaims beneficial ownership beyond his pecuniary interest.
MAIA Biotechnology, Inc. Chief Scientific Officer Sergei Gryaznov reported an open-market purchase of 2,000 shares of Common Stock on June 1, 2026 at a price of $1.345 per share. Following this transaction, he directly holds 46,511 shares of MAIA Biotechnology Common Stock.
MAIA Biotechnology, Inc. reported that Chief Executive Officer and 10% owner Vitoc Vlad received a grant of 800,000 stock options on May 29, 2026 under the company’s 2021 Equity Incentive Plan. These options allow him to buy common stock at an exercise price of $1.39 per share until May 29, 2036.
The grant is a compensation award rather than an open-market purchase. The options vest over four years, with 25% vesting on the first anniversary of the grant and the remaining 75% vesting monthly over the following 36 months, aligning his incentives with longer-term company performance.
MAIA Biotechnology, Inc. reported that Chief Scientific Officer Sergei Gryaznov received a grant of stock options covering 400,000 shares of common stock. These options have an exercise price of $1.39 per share and expire on May 29, 2036.
The grant was made under MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan. The options vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining options vesting monthly over the following 36 months.
MAIA Biotechnology, Inc. reported that Head of Finance Jeffrey C. Himmelreich received a grant of stock options covering 60,000 shares of common stock. The options have an exercise price of $1.39 per share and expire on May 29, 2036.
The award was granted under the company’s 2021 Equity Incentive Plan. The options vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining options vesting in equal monthly installments over the following 36 months.
MAIA Biotechnology, Inc. reported results of its 2026 annual shareholder meeting. As of the March 23, 2026 record date, 60,671,491 common shares were outstanding and entitled to vote, and 37,547,754 shares were present in person or by proxy, representing approximately 61.88%, so a quorum was reached.
Stockholders re-elected Class I directors Louie Ngar Yee and Steven Chaouki to three-year terms expiring at the 2029 annual meeting or until their successors are elected and qualified. Votes for Louie Ngar Yee were 16,658,677 for and 8,796,832 withheld, with 11,375,414 broker non-votes. Votes for Steven Chaouki were 25,109,811 for and 345,698 withheld, with 11,375,414 broker non-votes.
Shareholders also ratified the appointment of Grant Thornton LLP as independent registered public accounting firm for the year ending December 31, 2026, with 37,278,294 votes for, 210,408 against, and 19,052 abstentions.
MAIA Biotechnology, Inc. Schedule 13G discloses that Solas Capital Management, LLC and Frederick Tucker Golden report shared beneficial ownership of 4,297,004 shares of common stock. The filing states this represents 7.1% of the class based on 60,671,491 shares outstanding as of March 23, 2026.
The filing states Solas acts as investment manager to a private fund and sub-adviser to another fund and that each fund disclaims beneficial ownership under Rule 13d-4; voting and dispositive power are reported as shared for the listed 4,297,004 shares.
MAIA Biotechnology, Inc. has suspended sales of its common stock under its At The Market Offering Agreement with H.C. Wainwright & Co. and has given notice to terminate the agreement effective seven business days after May 14, 2026.
Under a March 28, 2025 prospectus supplement for up to $11,200,000, the company offered and sold 3,116,012 shares of common stock, generating gross proceeds of approximately $5,680,924 before ending use of this at-the-market program.
MAIA Biotechnology, Inc. is amending its shelf to report termination of its at-the-market program covering up to $11,200,000 of common stock. The company reports that, since the prior prospectus dated March 28, 2025, it sold 3,116,012 shares for gross proceeds of $5,680,924 under the sales agreement with H.C. Wainwright & Co.
On May 14, 2026 MAIA suspended sales under the sales agreement and provided notice to terminate the agreement and the related at-the-market offering; termination becomes effective seven business days after May 14, 2026. The supplement also terminates the prior prospectuses on the same schedule. The last reported sale price on the NYSE American was $1.36 per share on May 14, 2026.